{"id":1007747,"date":"2026-10-01T17:28:30","date_gmt":"2026-10-01T21:28:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/"},"modified":"2026-10-01T17:28:30","modified_gmt":"2026-10-01T21:28:30","slug":"axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/","title":{"rendered":"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair"},"content":{"rendered":"
\n

ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (\u201cAxogen\u201d or the \u201cCompany\u201d) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (\u201cBioCircuit\u201d), a privately held medical device company and developer of NerveTape\u2122.<\/p>\n

\u201cThis is a significant day for Axogen and the surgeons and patients we serve,\u201d said Michael Dale, President and Chief Executive Officer of Axogen. \u201cNerveTape represents a new standard of care as the first sutureless nerve repair option\u2014one that is simpler, faster, and more effective than microsuturing. This innovative technology directly addresses surgeons\u2019 everyday need to repair nerves and aligns perfectly with Axogen\u2019s mission to make the restoration of peripheral nerve function an expected standard of care. It is therefore an ideal fit with our direct sales organization and hospital contracting capabilities, enabling and unlocking NerveTape\u2019s full potential.\u201d<\/p>\n

The Company expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 and approximately $34 million to 2027 revenue. This contribution was not included in Axogen\u2019s most recently issued full-year 2026 guidance of at least 24% revenue growth. The Company continues to expect gross margin to be at least 73% and to be free cash positive for the full-year 2026.<\/p>\n

\n About Axogen<\/strong>\n <\/p>\n

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.<\/p>\n

Axogen\u2019s product portfolio includes Avance\u00ae<\/sup> (acellular nerve allograft-arwx), Avance\u00ae<\/sup> Nerve Graft, Axoguard Nerve Connector\u00ae<\/sup>, Axoguard Nerve Protector\u00ae<\/sup>, Axoguard HA+ Nerve Protector\u2122, Axoguard Nerve Cap\u00ae<\/sup>, and Avive+ Soft Tissue Matrix\u00ae<\/sup>.\u200b<\/p>\n

\n About BioCircuit Technologies<\/strong>\n <\/p>\n

BioCircuit Technologies, based in Atlanta, Georgia, develops and commercializes medical devices for peripheral nerve repair and neuromodulation, with expertise in biomaterials, precision Nitinol design and manufacturing, and bioelectronics for nerve stimulation and recording. Its first commercial product, NerveTape\u2122, is the first FDA-cleared sutureless device for repairing transected nerves. BioCircuit has been supported by small business funding from the National Institutes of Health along with private investment from Alsora Capital, GRA Venture Fund, Michael Masters of Masters Capital Management, and other investors. For more information, visit www.biocircuit.com.<\/p>\n

\n Cautionary Statements Concernin<\/strong>
\n g Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding Axogen\u2019s ability to successfully integrate BioCircuit and realize the anticipated benefits of the acquisition, the expected financial impact of the acquisition and related financial guidance and outlook, including expected revenue, revenue growth, revenue contribution from BioCircuit in the fourth quarter of 2026 and in 2027, gross margin, free cash flow, as well as expectations regarding the commercialization and adoption of NerveTape and the expansion of Axogen\u2019s addressable market. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201cupcoming\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties related to the integration of BioCircuit and the realization of the anticipated benefits of the acquisition and the risks and uncertainties inherent in Axogen\u2019s business, including the risks and uncertainties described in the Company\u2019s periodic filings with the SEC. The events and circumstances reflected in the Company\u2019s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Axogen can be found under the heading \u201cRisk Factors\u201d in Axogen\u2019s periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2025 and in its subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Axogen undertakes no obligation to update or revise any forward-looking statements contained herein.<\/p>\n

\n Media Contact:<\/strong>\n <\/p>\n

Axogen, Inc.
InvestorRelations@axogeninc.com<\/a><\/u><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (\u201cAxogen\u201d or the \u201cCompany\u201d) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (\u201cBioCircuit\u201d), a privately held medical device company and developer of NerveTape\u2122. \u201cThis is a significant day for Axogen and the surgeons and patients we serve,\u201d said Michael Dale, President and Chief Executive Officer of Axogen. \u201cNerveTape represents a new standard of care as the first sutureless nerve repair option\u2014one that is simpler, faster, and more effective than microsuturing. This innovative technology directly addresses surgeons\u2019 everyday need to repair nerves and … <\/p>\n

Continue reading “Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1007747","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAxogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (\u201cAxogen\u201d or the \u201cCompany\u201d) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (\u201cBioCircuit\u201d), a privately held medical device company and developer of NerveTape\u2122. \u201cThis is a significant day for Axogen and the surgeons and patients we serve,\u201d said Michael Dale, President and Chief Executive Officer of Axogen. \u201cNerveTape represents a new standard of care as the first sutureless nerve repair option\u2014one that is simpler, faster, and more effective than microsuturing. This innovative technology directly addresses surgeons\u2019 everyday need to repair nerves and … Continue reading "Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-01T21:28:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair\",\"datePublished\":\"2026-10-01T21:28:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/\"},\"wordCount\":831,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/\",\"name\":\"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg=\",\"datePublished\":\"2026-10-01T21:28:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/","og_locale":"en_US","og_type":"article","og_title":"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair - Market Newsdesk","og_description":"ALACHUA, Fla. and TAMPA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (\u201cAxogen\u201d or the \u201cCompany\u201d) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (\u201cBioCircuit\u201d), a privately held medical device company and developer of NerveTape\u2122. \u201cThis is a significant day for Axogen and the surgeons and patients we serve,\u201d said Michael Dale, President and Chief Executive Officer of Axogen. \u201cNerveTape represents a new standard of care as the first sutureless nerve repair option\u2014one that is simpler, faster, and more effective than microsuturing. This innovative technology directly addresses surgeons\u2019 everyday need to repair nerves and … Continue reading \"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-01T21:28:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair","datePublished":"2026-10-01T21:28:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/"},"wordCount":831,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/","name":"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg=","datePublished":"2026-10-01T21:28:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzODI5NSM3ODczMzgwIzIwMTA1MDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/axogen-completes-acquisition-of-biocircuit-technologies-adding-nervetape-the-first-fda-cleared-device-for-sutureless-peripheral-nerve-repair\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape\u2122, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1007747"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007747\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1007747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1007747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1007747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}